Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Total stock-based compensation expense	$ 1,931	$ 2,245	$ 5,716	$ 9,171
Lucid Diagnostics Inc [Member]
Total stock-based compensation expense	955	1,252	3,089	5,859
Cost Of Revenue [Member]
Total stock-based compensation expense	32	32	112	86
Selling and Marketing Expense [Member]
Total stock-based compensation expense	292	403	1,082	1,302
General and Administrative Expense [Member]
Total stock-based compensation expense	1,426	1,499	3,717	6,761
Research and Development Expense [Member]
Total stock-based compensation expense	181	311	805	1,022
Lucid Diagnostics 2018 Equity Plan [Member] | Cost Of Revenue [Member]
Total stock-based compensation expense	24	16	81	44
Lucid Diagnostics 2018 Equity Plan [Member] | Selling and Marketing Expense [Member]
Total stock-based compensation expense	252	228	849	697
Lucid Diagnostics 2018 Equity Plan [Member] | General and Administrative Expense [Member]
Total stock-based compensation expense	548	721	1,484	4,069
Lucid Diagnostics 2018 Equity Plan [Member] | Research and Development Expense [Member]
Total stock-based compensation expense	98	67	356	204
PAVmed Inc 2014 Equity Plan [Member] | Cost Of Revenue [Member]
Total stock-based compensation expense	9	10	30	26
PAVmed Inc 2014 Equity Plan [Member] | Selling and Marketing Expense [Member]
Total stock-based compensation expense	18	106	136	359
PAVmed Inc 2014 Equity Plan [Member] | General and Administrative Expense [Member]
Total stock-based compensation expense	1	7	5	170
PAVmed Inc 2014 Equity Plan [Member] | Research and Development Expense [Member]
Total stock-based compensation expense	$ 5	$ 97	$ 148	$ 290